Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Role of PCSK9 Inhibitors in Patients Treated with Immune Checkpoint Inhibitors for Cancer

  • By

  • Chuan Angel Lu

  • Changchuan Jiang

  • Andrew Z. Wang

  • Tian Zhang

  • May 29, 2026

Share

Original Source(s)

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

  • by Chuan Angel Lu, Changchuan Jiang, Andrew Z. Wang, Tian Zhang

  • May 29, 2026

Related Content

Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma